Semi-annual report_Semi-annual report_Joincare Pharmaceutical Group Industry Co., Ltd.

简体中文 | English



Investor Relations

Listed on the Shanghai Stock Exchange in June 2001, with a maximum market value of 47.5 billion



Your location：

Homepage

Investor Relations

Semi-annual report

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Livzon Group Entering into The License Agreement

Categories:

Announcement

Time:

2023-03-10 17:30:00
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Company's Obtaining the Certificate of High and New Technology Enterprise

Categories:

Announcement

Time:

2023-02-16 15:30:00
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Acceptance of Application for Drug Marketing Approval

Categories:

Announcement

Time:

2023-02-08 18:00:00
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining Drug Registration Certificate of Voriconazole for Injection

Categories:

Announcement

Time:

2023-01-31 17:30:00
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Number of Underlying Shares in Respect of the Outstanding GDRs Being less than 50% of the Number Approved by the CSRC

Categories:

Announcement

Time:

2023-01-30 18:20:00
Ad hoc announcement pursuant to Art. 53 LR-JACRE Announcement on Grant of Registration Approval for Tocilizumab Injection

Categories:

Announcement

Time:

2023-01-19 09:00:00
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Approval for Clinical Trials of Asenapine Transdermal Patch

Categories:

Announcement

Time:

2023-01-13 18:00:00
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Upcoming Expiration of the Redemption Lock-up Period of GDRs

Categories:

Announcement

Time:

2023-01-13 18:00:00
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Setting Up of a Joint Venture with Its Controlled Subsidiary Livzon Group

Categories:

Announcement

Time:

2022-12-12 17:30:00
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Co-Investment with Livzon Group, the Controlled Subsidiary

Categories:

Announcement

Time:

2022-11-28 17:30:00

Page up

Page down

Quick Navigation

Product

Online Mall

0755-33268688

Service Hotline

Quick

Navigation

Service

Hotline

0755-33268688

Joincare Pharmaceutical Group Industry Co., Ltd.

Official WeChat Official Account

Corporate Governance

Subscribe

Investor Service

Financial reports

Corporate Calendar

GDR release information

Corporate Governance

Subscribe

Investor Service

Financial reports

Corporate Calendar

GDR release information

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Livzon Group Entering into The License Agreement

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Company's Obtaining the Certificate of High and New Technology Enterprise

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Acceptance of Application for Drug Marketing Approval

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining Drug Registration Certificate of Voriconazole for Injection

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Number of Underlying Shares in Respect of the Outstanding GDRs Being less than 50% of the Number Approved by the CSRC

Ad hoc announcement pursuant to Art. 53 LR-JACRE Announcement on Grant of Registration Approval for Tocilizumab Injection

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Approval for Clinical Trials of Asenapine Transdermal Patch

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Upcoming Expiration of the Redemption Lock-up Period of GDRs

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Setting Up of a Joint Venture with Its Controlled Subsidiary Livzon Group

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Co-Investment with Livzon Group, the Controlled Subsidiary